BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 17493384)

  • 21. Assessment of topoisomerase II-alpha gene status by dual color chromogenic
    Neama RAA; Habib MA; Ali SA; Al-Khafaji AH; Alqanbar MF
    Indian J Pathol Microbiol; 2017; 60(4):475-480. PubMed ID: 29323058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
    Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
    Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER-2/neu and topoisomerase-II-alpha expression and genic amplification in pancreatic adenocarcinoma.
    Baiocchi GL; Villanacci V; Rossi E; Gheza F; Portolani N; Giulini SM
    Dig Dis Sci; 2009 Sep; 54(9):2049-51. PubMed ID: 19582575
    [No Abstract]   [Full Text] [Related]  

  • 24. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
    Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P
    J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
    Press MF; Sauter G; Buyse M; Bernstein L; Guzman R; Santiago A; Villalobos IE; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Bee V; Taupin H; Flom KJ; Tabah-Fisch I; Pauletti G; Lindsay MA; Riva A; Slamon DJ
    J Clin Oncol; 2011 Mar; 29(7):859-67. PubMed ID: 21189395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization.
    Murthy SK; Magliocco AM; Demetrick DJ
    Arch Pathol Lab Med; 2005 Jan; 129(1):39-46. PubMed ID: 15628907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
    Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
    Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.
    Chen JR; Chien HP; Chen KS; Hwang CC; Chen HY; Yeh KY; Hsieh TY; Chang LC; Hsu YC; Lu RJ; Hua CC
    Medicine (Baltimore); 2017 Jan; 96(2):e5582. PubMed ID: 28079792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma.
    Rossi E; Villanacci V; Bassotti G; Donato F; Festa A; Cengia G; Grisanti S; Cestari R
    Histopathology; 2010 Jul; 57(1):81-9. PubMed ID: 20557373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER-2 and TOP2A coamplification in urinary bladder cancer.
    Simon R; Atefy R; Wagner U; Forster T; Fijan A; Bruderer J; Wilber K; Mihatsch MJ; Gasser T; Sauter G
    Int J Cancer; 2003 Dec; 107(5):764-72. PubMed ID: 14566826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
    Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS
    Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer.
    Glynn RW; Mahon S; Curran C; Callagy G; Miller N; Kerin MJ
    Oncologist; 2011; 16(7):949-55. PubMed ID: 21705665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Fountzilas G; Christodoulou C; Bobos M; Kotoula V; Eleftheraki AG; Xanthakis I; Batistatou A; Pentheroudakis G; Xiros N; Papaspirou I; Koumarianou A; Papakostas P; Bafaloukos D; Skarlos DV; Kalogeras KT
    J Transl Med; 2012 Oct; 10():212. PubMed ID: 23092535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TOP2A amplification and overexpression in hepatocellular carcinoma tissues.
    Panvichian R; Tantiwetrueangdet A; Angkathunyakul N; Leelaudomlipi S
    Biomed Res Int; 2015; 2015():381602. PubMed ID: 25695068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics.
    Fasching PA; Weihbrecht S; Haeberle L; Gasparyan A; Villalobos IE; Ma Y; Ekici AB; Wachter DL; Hartmann A; Beckmann MW; Slamon DJ; Press MF
    Breast Cancer Res Treat; 2014 May; 145(1):193-203. PubMed ID: 24682655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.
    Personeni N; Baretti M; Bozzarelli S; Spaggiari P; Rubino L; Tronconi MC; Fumagalli Romario U; Rosati R; Giordano L; Roncalli M; Santoro A; Rimassa L
    Gastric Cancer; 2017 May; 20(3):428-437. PubMed ID: 27530622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer.
    Partanen L; Staaf J; Tanner M; Tuominen VJ; Borg Å; Isola J
    Genes Chromosomes Cancer; 2012 Sep; 51(9):832-40. PubMed ID: 22585709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
    Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
    Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.